Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cyclerion Therapeutics Inc (CYCN)

Cyclerion Therapeutics Inc (CYCN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,006
  • Shares Outstanding, K 3,925
  • Annual Sales, $ 2,000 K
  • Annual Income, $ -3,060 K
  • EBIT $ -4 M
  • EBITDA $ -4 M
  • 60-Month Beta 0.96
  • Price/Sales 1.53
  • Price/Cash Flow N/A
  • Price/Book 0.60

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1600 +29.73%
on 12/30/25
2.2800 -34.00%
on 01/06/26
-0.0051 (-0.34%)
since 12/12/25
3-Month
1.1600 +29.73%
on 12/30/25
2.4599 -38.82%
on 10/16/25
-0.8651 (-36.50%)
since 10/14/25
52-Week
1.1600 +29.73%
on 12/30/25
6.2500 -75.92%
on 02/03/25
-1.4151 (-48.46%)
since 01/14/25

Most Recent Stories

More News
Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression

– Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaboration Agreement with Medsteer – – Comprehensive Business Update and Path to Initiating Phase...

CYCN : 1.5500 (+1.31%)
Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company

– Cyclerion Relaunches, Advancing a Phase 2–Ready Program for Millions Living with Treatment-Resistant Depression Through MIT License Agreement – – Webcast to be held September 24, 2025...

CYCN : 1.5500 (+1.31%)
Cyclerion Therapeutics Advances Growth Strategy with Key License Amendments and Asset Evaluations

Cyclerion Therapeutics updates on strategic growth, leveraging sGC assets, reducing expenses, and progressing with asset evaluations and agreements.Quiver AI SummaryCyclerion Therapeutics, Inc. has provided...

CYCN : 1.5500 (+1.31%)
Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth

CYCN : 1.5500 (+1.31%)
Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results

Positive topline results for CY6463 announced in two clinical studies in patients with Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like...

CYCN : 1.5500 (+1.31%)
Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics’ Board of Directors

Renowned neuroscience leader to further long-term clinical research strategy and external collaborations...

CYCN : 1.5500 (+1.31%)
Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation

Data for CY6463, a first-in-class, CNS-penetrant, sGC stimulator, demonstrate safety and positive effects across biomarkers of disease in MELAS patients ...

CYCN : 1.5500 (+1.31%)
Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation

Company to discuss positive topline and additional clinical data for CY6463 in MELAS patients Mitochondrial disease clinician-researcher, Amel Karaa,...

CYCN : 1.5500 (+1.31%)
Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease

CY6463 alleviated mitochondrial dysfunction and reduced inflammation in preclinical models of mitochondrial complex 1 deficiency Data provide support for...

CYCN : 1.5500 (+1.31%)
Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium

Data from an eight-patient, open-label study demonstrate improvements across multiple biomarkers of mitochondrial function, inflammation, cerebral blood...

CYCN : 1.5500 (+1.31%)

Business Summary

Cyclerion Therapeutics Inc. is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. The company's product pipeline consists of Olinciguat, Praliciguat and IW-6463 which are in...

See More

Key Turning Points

3rd Resistance Point 1.8467
2nd Resistance Point 1.7833
1st Resistance Point 1.6567
Last Price 1.5500
1st Support Level 1.4667
2nd Support Level 1.4033
3rd Support Level 1.2767

See More

52-Week High 6.2500
Fibonacci 61.8% 4.3056
Fibonacci 50% 3.7050
Fibonacci 38.2% 3.1044
Last Price 1.5500
52-Week Low 1.1600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar